Platt Assists PharmAthene in Procuring $78.4 Million in Additional Funding from HHS

February 26, 2010

Pardon Our Dust

We recently launched this new site and are still in the process of updating some of our archived content. Some details of this article may be incomplete, links may be broken, and other elements may not display properly yet. We appreciate your patience and understanding.


MWC specifically assisted PharmAthene, an Annapolis-based biodefense company specializing in medical countermeasures against chemical and biological threats, in its efforts to reach out to Congress and the Obama administration to ensure that both the Biological Advanced Research and Development Agency (BARDA) at HHS and the Office of Chemical and Biological Counter-Measures at the Department of Defense were adequately funded so that research monies for this Generation II anthrax vaccine, and other research, was available. Without the legislative and executive branch outreach and the subsequent grant secured with the contract modification, PharmAthene’s research was going to be suspended due to lack of resources. To read the PharmAthene press release, click on the attached PDF file.